How CAR-NK Cells Could Work Better than CAR-T Cells
James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
”The major hurdle addressed is donor cell rejection by the recipient’s immune system, which the authors determined is primarily mediated by host CD8+ T cells.
To overcome rejection, the researchers engineered a single gene construct that combines a selective shRNA to knock down rejection-related HLA Class I molecules, a Chimeric Antigen Receptor (CAR) for tumor targeting, and the expression of immune checkpoint ligands like PD-L1 or single-chain HLA-E (SCE).
This integrated approach not only enabled the CAR-NK cells to evade host-mediated rejection in mouse models but also surprisingly enhanced their anti-tumor activity and provided a favorable safety profile by reducing inflammatory cytokines.”
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis